Skip to content

Clinical efficacy of therapy with recombinant human Interferona2a in patients with severe fever with thrombocytopenia syndrome

Clinical efficacy of therapy with recombinant human Interferona2a in patients with severe fever with thrombocytopenia syndrome

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-15006285
Enrollment
Unknown
Registered
2015-04-21
Start date
2015-04-20
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

severe fever with thrombocytopenia syndrome

Interventions

therapy group:supportive and symptomatic treatment+therapy with Interferon

Sponsors

Beijing Institute of Microbiology and Epidemiology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 100 Years

Inclusion criteria

Inclusion criteria: Based on the criteria of severe fever with thrombocytopenia syndrome as defined by the Chinese Ministry of Health.

Exclusion criteria

Exclusion criteria: 1. patients who accepted anti-virus treatment within 6 months; 2. patients with acute infection of HBV, HCV, HIV, syphilis or pathogens can cause similar symptoms with SFTSV(such as rickettsiae, borrelia burgdor feri and babesia); 3. patients who was unwilling or unable to sign the informed consent form; 4. patients who are participating other clinical trial than the current research; 5. patients who are unsuitable for the trial for other reasons according to the researcher's evaluation.

Design outcomes

Primary

MeasureTime frame
case fatality rate of severe fever with thrombocytopenia syndrome;Viral load clearance rate of severe fever with thrombocytopenia syndrome virus;

Secondary

MeasureTime frame
days for platelet and white blood cells recovered to the normal level;time for the main clinical symptom disappeared;time for blood biochemical parameters recovered to the normal level;Blood;

Countries

China

Contacts

Public ContactLiu Wei
lwbime@163.com+86 010-66948499

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026